Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration

Bayer

Status and phase

Completed

Phase 1

Conditions

Hemophilia A

Treatments

Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Biological: BAY94-9027 + Recombinant Factor VIII (Kogenate FS, BAY14-2222))

Study type

Interventional

Funder types

Industry

Identifiers

NCT01184820

13401

Details and patient eligibility

About

The purpose of this study is to describe the pharmacokinetics (PK) of BAY94-9027(the test drug). Pharmacokinetics means that we will measure how well the study drug corrects the factor VIII levels in your blood and how long it takes for the levels to fall back to your baseline level. The study is also designed to determine if the pharmacokinetics of BAY94-9027 change following repeat dosing over 8 weeks, determine if BAY94-9027 is safe, tolerable, and effective for the treatment of severe hemophilia A and define the appropriate dose of BAY94-9027. Two doses of BAY94-9027 will be studied.

The first 8 subjects enrolled in the study (cohort 1) will receive a low dose (25 IU/kg) and will be treated 2 days a week for 8 weeks (total of 16 doses). The second 8 subjects (cohort 2) will receive a higher dose and will be treated 1 day a week for 8 weeks (total 8 doses). All subjects will receive a single dose of rFVIII (Bayer Kogenate FS) to determine the PK by measuring blood levels for 2 days before they start the study drug BAY94-9027. Factor VIII blood levels for BAY94-9027 will be measured for 7 days after the first and last dose to see describe the PK. Safety & tolerability assessment include vital signs, coagulation and hematological parameter, clinical chemistry, measurement of FVIII inhibitor and polyethylene glycol (PEG) antibodies will be done during the course of the study.

Enrollment

14 patients

Sex

Male

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male subjects with severe hemophilia A (documented plasma baseline Factor VIII level <1 %)
>/= 18 but </= 65 years of age
Previously treated with Factor VIII concentrate(s) for a minimum of 150 exposure days (as supported by the subject's medical history)
Immunocompetent with a CD4+ lymphocyte count > 400/mm³
Signed informed consent from subject

Exclusion criteria

Documented history of inhibitor to Factor VIII with a titer >/= 0.6 BU (Biological Unit), by the Nijmegen modified assay. However, subjects with a maximum historical titer of </= 1.0 BU with the classical Bethesda assay on a single measurement but with at least 3 subsequent successive negative results (< 0.6 BU) thereafter are eligible.
Unable to stop Factor VIII treatment to complete a minimum 72 hour washout
Current evidence of inhibitor to Factor VIII with a titer >/= 0.6 BU, measured at the time of screening
Abnormal renal function (serum creatinine > 1.5 times the upper limit of the normal range)
Total bilirubin > 1.5 times the upper limit of the normal range
Active hepatic disease (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels > 2 times the upper limit of the normal range)
Any concomitant coagulation disorder other than hemophilia A (including lupus anticoagulant)
Platelet count < 100,000/mm³
Within the last 3 months prior to study entry or during the study will be treated with an immunomodulating drug other than anti-retroviral chemotherapy (e.g., a interferon, steroids, rituximab, etc)
Any subject who requires major surgery during study period. Minor procedures may be approved if discussed in advance with the medical expert.